The Gallium-68 PET/CT scan is a type of PET scan based on similar technology to octreotide imaging. PET imaging using the Gallium-68 labeled compound DOTATATE offers higher resolution than octreotide scans. Because it binds very strongly to the somatostatin receptor of the neuroendocrine tumor cells, it can be more effective at detecting very small tumors and metastases.
This type of PET/CT scan, with 68Ga-DOTATATE, has been around for over 10 years in Europe. Vanderbilt was the first institution in America to use the Gallium-68 PET/CT scan to detect neuroendocrine tumors.
Phase 1 of the Gallium-68 PET/CT scan clinical trial is completed. Phase 2 will begin in late 2012 or early 2013; we will update this page with the latest information.